
PartnershipAug 10, 2026, 04:04 PM
Alamar Expands Neurodegenerative Disease Partnership for 86,000 Samples
AI Summary
Alamar Biosciences, Inc. announced an expansion of its strategic partnership with the Alzheimer's Disease Data Initiative and Gates Ventures. This collaboration will involve profiling an additional 86,000 plasma samples using the company's NULISAseq Neuro 220 panel, aiming to advance the understanding of neurodegenerative diseases. The combined dataset is expected to reach over 140,000 samples by 2027, representing the largest study of its kind.
Key Highlights
- Alamar Biosciences expanded its strategic partnership with Alzheimer's Disease Data Initiative and Gates Ventures.
- The expanded agreement adds profiling of 86,000 plasma samples.
- The NULISAseq Neuro 220 panel will be used for profiling.
- Approximately 21,000 samples are part of a national-scale proteomics initiative.
- This builds on a June 2025 initiative that profiled over 55,000 samples.
- The combined dataset is projected to encompass over 140,000 samples by 2027.
- The Neuro 220 panel measures approximately 220 neurological biomarker targets.
- The panel includes eMTBR-Tau, an emerging biomarker for tau tangle burden.
Price Impact
More from ALMR